Tianjin Chase Sun Pharmaceutical Co (SZSE:300026) ROCE % : 1.74% (As of Sep. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Tianjin Chase Sun Pharmaceutical Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tianjin Chase Sun Pharmaceutical Co's annualized ROCE % for the quarter that ended in Sep. 2024 was 1.74%.

Tianjin Chase Sun Pharmaceutical Co ROCE % Historical Data

The historical data trend for Tianjin Chase Sun Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Chase Sun Pharmaceutical Co ROCE % Chart

Tianjin Chase Sun Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

7.16

9.42

10.34

8.05

6.60

Tianjin Chase Sun Pharmaceutical Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															7.61	1.08	3.57	4.11	1.74

Tianjin Chase Sun Pharmaceutical Co ROCE % Calculation

Tianjin Chase Sun Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	668.397	/	( ( (12659.664 - 2677.905)	+	(11835.032 - 1564.848) )	/ 2 )
	=	668.397	/	( (9981.759	+	10270.184)	/ 2 )
	=	668.397	/	10125.9715
	=	6.60 %

Tianjin Chase Sun Pharmaceutical Co's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	174.248	/	( ( (12024.565 - 1681.234)	+	(11371.586 - 1669.22) )	/ 2 )
	=	174.248	/	( ( 10343.331	+	9702.366 )	/ 2 )
	=	174.248	/	10022.8485
	=	1.74 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Tianjin Chase Sun Pharmaceutical Co (SZSE:300026) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tianjin Chase Sun Pharmaceutical Co ROCE % Related Terms

Thank you for viewing the detailed overview of Tianjin Chase Sun Pharmaceutical Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tianjin Chase Sun Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Chase Sun Pharmaceutical Co Ltd (SZSE:300026) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

No. 20, Quanfa Road, Tianjin Wuqing Development Area, Tianjin, CHN, 301700

Website

http://www.chasesun.cn

Tianjin Chase Sun Pharmaceutical Co Ltd is a high-tech medicine and health industry group. The company offers Chinese herb preparation products, medicinal granules, synthetic drugs, biotech drugs, medical apparatus, and Internet-based therapy.

Executives

Yao Xiao Qing	Director
Chen Rui Qiang	Executives
Li Chun Xu	Executives
Lan Wu Jun	Directors, Directors, and Executives
Zheng Dan	Directors, executives
Zhang Kun	Executives
Gao Guo Wei	Executives
Shang Xiao Mei	Securities Affairs Representative
Sun Zhang Hai	Director
Wu Guang Ning	Supervisors
Wang Long	Executives
Liu Qiang	Supervisors
Ceng Guo Zhuang	Director
Su Bing Jun	Directors, executives
Nie Wei	Supervisors

Tianjin Chase Sun Pharmaceutical Co Headlines

No Headlines